etanercept

Autoimmune drug pipeline: What health execs should watchNew drugs for RA, psoriasis, type 1 diabetes and Crohn’s disease—some recently approved and others coming down the pipeline—could have an impact on the industry.
TNF inhibitor treatment tacticsWith a long history in dermatology and rheumatology, TNF inhibitors can not only improve psoriasis and psoriatic arthritis, but they also may reduce comorbid cardiovascular risks and work better combined with methotrexate. Low doses of cyclosporine may be effective at treating the psoriasis reaction when topicals have proven ineffective. Aggressively managing TNF-induced reactions can help patients stay on drugs that are working for other challenging diseases.
TNF alfpha inhibitor safety, efficacy data growsLong-term follow-up studies and drug registries continue to deliver reassuring data regarding the safety and efficacy of TNF inhibitors, an expert says.
Express Scripts’ 2016 Drug Trend Report: 7 things to knowReport highlights spending trends in key areas, including specialty medications, oncology, diabetes, and inflammatory conditions.
Clear skin within reach for psoriasis patientsNew data presented at the 25th European Academy of Dermatology and Venereology (EADV) Congress in Vienna, Austria, this week shows that secukinumab (Cosentyx, Novartis) has long-lasting skin clearance in patients with moderate-to-severe plaque psoriasis.
New biosimilar for RA to save millionsFDA’s approval of a new biosimilar—the third FDA-approved biosimilar—stands to save the US healthcare system millions of dollars.
Remicade will now have a biosimilarExpert: Expectations are high that biosimilars can control overall biologic cost growth.
Assessing the impact of biosimilars on cost, qualityA new report from IMS Institute for Healthcare Informatics finds that biosimilar acceptance will grow and drive change in the healthcare system.
New rheumatoid arthritis therapies are comingFour new drugs and a biosimilar should be on your radar.
New psoriasis therapies must demonstrate valuePsoriasis affects a small percentage of the population but price increases for drug treatments have outpaced the Consumer Price Index.